All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-03-01T11:27:33.000Z

A phase I/II trial of pirtobrutinib in patients with R/R Waldenstrom’s macroglobulinemia (BRUIN trial)

Mar 1, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in Waldenstrom’s macroglobulinemia.

Bookmark this article

The Lymphoma Hub is happy to present a visual abstract representing key data from the phase I/II BRUIN trial (NCT03740529) evaluating the safety and efficacy of pirtobrutinib, a reversible (non-covalent) Bruton’s tyrosine kinase inhibitor, in heavily pretreated patients with relapsed/refractory Waldenstrom’s macroglobulinemia, as presented at the 64th American Society of Hematology Annual Meeting and Exposition. In June 2021, the Lymphoma Hub reported preliminary results of the trial.


 

Visual Abstract

To download this visual abstract, click below.

Download here

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox